Difference between revisions of "Essential thrombocythemia"
Jump to navigation
Jump to search
m |
m |
||
Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
+ | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
+ | |- | ||
+ | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | ||
+ | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
+ | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Untreated= | =Untreated= | ||
− | ==Anagrelide (Agrylin)== | + | ==Anagrelide (Agrylin) {{#subobject:fdd555|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen #1, Harrison et al. 2005=== | + | ===Regimen #1, Harrison et al. 2005 {{#subobject:bbeb21|Variant=1}}=== |
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | *[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | ||
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | *[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | ||
− | ===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)=== | + | ===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET) {{#subobject:abf053|Variant=1}}=== |
− | *[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal ( | + | *[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") |
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | *Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | ||
Line 21: | Line 30: | ||
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | # Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | ||
− | ==Hydroxyurea (Hydrea)== | + | ==Hydroxyurea (Hydrea) {{#subobject:762af3|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen #1, Harrison et al. 2005=== | + | ===Regimen #1, Harrison et al. 2005 {{#subobject:d87ecc|Variant=1}}=== |
*[[Hydroxyurea (Hydrea)]] 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | *[[Hydroxyurea (Hydrea)]] 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | ||
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | *[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | ||
− | ===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)=== | + | ===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET) {{#subobject:53255b|Variant=1}}=== |
− | *[[Hydroxyurea (Hydrea)]] 1500 mg PO once daily ("increased until maintenance of the platelet count at normal ( | + | *[[Hydroxyurea (Hydrea)]] 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") |
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | *Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | ||
Revision as of 01:43, 9 February 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
8 regimens on this page
9 variants on this page
|
Untreated
Anagrelide (Agrylin)
back to top |
Regimen #1, Harrison et al. 2005
- Anagrelide (Agrylin) 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
- Aspirin 75 mg (100 mg in Australia) PO once daily
Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)
- Anagrelide (Agrylin) 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
- Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
References
- Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed content property of HemOnc.org
- Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed
Hydroxyurea (Hydrea)
back to top |
Regimen #1, Harrison et al. 2005
- Hydroxyurea (Hydrea) 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
- Aspirin 75 mg (100 mg in Australia) PO once daily
Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)
- Hydroxyurea (Hydrea) 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
- Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
References
- Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
- Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed